Shamburg News · 8-K filed Nov 13, 2026, 4:24 PM EST

Annovis Bio Reports Third Quarter 2026 Results and DUET-AD Trial Milestones

ANVS · Annovis Bio, Inc.

  • Earnings
  • Financing
  • Other event
  • Materiality: high

Annovis Bio, Inc. reported a net loss of $9,462,136, or $0.22 per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of $7,262,658, or $0.37 per share, a year earlier. Research and development expenses were $15.8 million for the quarter, against $6.3 million a year earlier, and cash and cash equivalents totaled $2.8 million at quarter end. The company also reported a $21.0 million underwritten public offering closed on November 6, 2026, and expects last patient, last visit in DUET-AD on December 31, 2026 with topline results in March 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001104659-26-127094.

Written from the filing by Shamburg Markets. Figures are as reported by the company.